Seidinger Ana Luiza, Fortes Fernanda Paschoal, Mastellaro Maria José, Cardinalli Izilda Aparecida, Zambaldi Lilian Girotto, Aguiar Simone Santos, Yunes José Andrés
Molecular Biology Laboratory, Boldrini Children's Center, Campinas, Sao Paulo, Brazil.
Pediatric Oncology Department, Boldrini Children's Center, Campinas, Sao Paulo, Brazil.
PLoS One. 2015 Oct 9;10(10):e0140356. doi: 10.1371/journal.pone.0140356. eCollection 2015.
The high incidence of adrenocortical tumors and choroid plexus carcinoma in children from South and Southeastern regions of Brazil is associated with the germline p.R337H mutation of TP53 gene. The concomitant occurrence of neuroblastoma and adrenocortical tumors in pediatric patients harboring the p.R337H mutation at our institution prompted us to investigate the putative association between p.R337H and pediatric neuroblastoma. Genomic DNA samples from 83 neuroblastoma patients referred to a single institution during the period of 2000-2014 were screened for the p.R337H mutation. Available samples from carriers were investigated for both nuclear p53 accumulation and loss of heterozigosity in tumor. Clinical data were obtained from medical records in order to assess the impact of 337H allele on manifestation of the disease. Seven out 83 neuroblastoma patients (8.4%) were carriers of the TP53 p.R337H mutation in our cohort. Immunohistochemical analysis of p.R337H-positive tumors revealed nuclear p53 accumulation. Loss of heterozigosity was not found among available samples. The presence of 337H allele was associated with increased proportion of stage I tumors. Our data indicate that in addition to adrenocortical tumors, choroid plexus carcinoma, breast cancer and osteosarcoma, genetic counseling and clinical surveillance should consider neuroblastoma as a potential neoplasia affecting p.R337H carriers.
巴西南部和东南部地区儿童肾上腺皮质肿瘤和脉络丛癌的高发病率与TP53基因的胚系p.R337H突变有关。在我们机构中,携带p.R337H突变的儿科患者同时发生神经母细胞瘤和肾上腺皮质肿瘤,这促使我们研究p.R337H与小儿神经母细胞瘤之间的假定关联。对2000年至2014年期间转诊至单一机构的83例神经母细胞瘤患者的基因组DNA样本进行p.R337H突变筛查。对携带者的可用样本进行肿瘤细胞核p53积累和杂合性缺失的研究。从医疗记录中获取临床数据,以评估337H等位基因对疾病表现的影响。在我们的队列中,83例神经母细胞瘤患者中有7例(8.4%)是TP53 p.R337H突变的携带者。对p.R337H阳性肿瘤的免疫组织化学分析显示细胞核p53积累。在可用样本中未发现杂合性缺失。337H等位基因的存在与I期肿瘤比例增加有关。我们的数据表明,除了肾上腺皮质肿瘤、脉络丛癌、乳腺癌和骨肉瘤外,遗传咨询和临床监测应将神经母细胞瘤视为影响p.R337H携带者的潜在肿瘤。